As the world seeks to win the battle through their vaccine campaign against COVID-19 pandemic disease, the impact of vaccines on asymptomatic coronavirus patients is still unknown. Now, research has shown that Pfizer-BioNTech and Moderna messenger RNA (mRNA) can significantly reduce the risk of asymptomatic coronavirus infection.
Researchers from the Mayo Clinic in the US found that several vaccines are now clinically available under emergency use authorization and have shown efficacy against asymptomatic COVID-19.
The study found that asymavomatic coronavirus patients (who show no signs or symptoms of the disease on contracting it for the entire incubation period) are much more likely to test for progressive and uncontrolled transmission of COVID- 19 ten days after the second dose of messenger RNA vaccine, compared with those who did not receive the vaccine.
Coronavirus vaccines of the Pfizer-BioNTech and Moderna RNA (mRNA) messenger are authorized for emergency use in many countries.
As per the study, asymptomatic coronavirus patients showed an 80 percent altered risk of a positive test for the disease after two doses of the COVID-19 mRNA vaccine. As according to the official Moderna website, “mRNA drugs are sets of instructions that cells in the body use to make proteins to prevent or fight disease.” In other words, mRNA vaccination is based on the regions of the genetic material, or RNA, of the coronavirus novel.
’72 per cent less likely to test positive after first dose of mRNA vaccine ‘
The findings, published in the journal Clinical Infectious Diseases, explain the effectiveness of Moderna coronavirus vaccines on coronavirus patients without any symptoms. Aaron Tande, Mayo Clinic infectious disease specialist and co-author of the paper, says, “We have found that these asymptomatic patients receive at least one dose of the first COVID-19 mRNA vaccine. authorized, Pfizer-BioNTech, 10 days or more. prior to screening 72 percent were less likely to test positive. “
“Those receiving two doses were 73 percent more likely, compared to the unvaccinated group,” Tande said.
The findings were published by the researchers after looking at a group of 39,000 patients. They underwent preclinical molecular screening tests for COVID-19. More than 48,000 screening tests were performed, including 3,000 on patients who had received at least one dose of COVID-19 mRNA vaccine.
Informing more about the screening tests, the researchers explained that these screenings were part of a routine Coronavirus test before treatments such as surgeries and other procedures.